Highlights Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.909 ^USD	+10.18%		+45.53%	-35.07%

Apr. 26	Foreign automakers eager for Chinese partners at Beijing auto show	RE
Apr. 25	Battle for 'tech luxury' in China as EVs get smarter - and cheaper	RE

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foreign automakers eager for Chinese partners at Beijing auto show	Apr. 26	RE
Battle for 'tech luxury' in China as EVs get smarter - and cheaper	Apr. 25	RE
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	Apr. 09	CI
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment	Jan. 09	DJ
Seres Therapeutics Announces VOWST? Commercial Launch Update and US FDA Fast Track Designation for SER-155	Jan. 09	CI
Earnings Flash (MCRB) SERES THERAPEUTICS Reports Q3 Revenue $310,000, vs. Street Est of $850,000	Nov. 02	MT
Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (MCRB) SERES THERAPEUTICS Posts Q2 Revenue $126.5M	23-08-08	MT
Seres Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023	23-06-17	CI
Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST	23-06-05	CI
Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™	23-06-05	CI
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome	23-05-09	CI
Seres Therapeutics, Inc. and Nestle Health Science Announce FDA Approval of VOWSTTM for Prevention of Recurrence of C. Difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI	23-04-26	CI
U.S. Food and Drug Administration Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides Difficile Infection to Seres Therapeutics, Inc	23-04-26	CI
US FDA approves Seres Therapeutics' pill for deadly C. difficile infections	23-04-26	RE
Seres Therapeutics' Q4 Net Loss Widens	23-03-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Highlights

Filters